Daily non-political popular news in brief.
Some key laboratory breast cancer cell lines are, indeed, good models for the 'real' disease
11-02-2006 · EurekAlert!In this era of molecular medicine, controversy among cancer researchers is increasing as to whether the laboratory cells they study -- and upon which human treatment is based -- accurately reflect the biology of "real" tumors growing in a person's body.
Read more »
Keywords: key, laboratory, breast, cancer, cell, lines, indeed, good, models, real, disease, line, model
« Previous | Next »
Similar news on "Some key laboratory breast cancer cell lines are, indeed, good models for the 'real' disease":
- Researchers identify unusual molecular switch for common form of advanced breast cancer
11-08-2007 · EurekAlert!
New evidence demonstrates that a novel molecular switch is involved in the development of a common form of advanced breast cancer, known as locally advanced breast cancer. The research, published by Cell Press in the Nov. 9, 2007 issue of Molecular Cell, provides an exciting paradigm shift in the understanding of a key event in breast cancer development and presents new therapeutic opportunities for this deadly disease.
Similar news · Read more »
- New weapon to fight leukemia
08-23-2007 · EurekAlert!
A new study indicates that the drug FTY720 prevents disease in a mouse model of two leukemias -- blast crisis chronic myeloid leukemia and acute lymphocytic leukemia -- caused by the cancer protein BCR-ABL. As the drug also induced cell lines from humans with these leukemias to die in vitro the authors suggest that FTY720 should be considered by researchers and clinicians developing new approaches to treat CML-BC and ALL.
Similar news · Read more »
- A study by the MUHC and McGill University opens a new door to understanding cancer
08-09-2007 · EurekAlert!
An in-depth understanding of the mechanisms that trigger cancer cell growth is vital to the development of more targeted treatments for the disease. An article published in the Aug. 3 issue of Molecular Cell provides a key to these mechanisms that may prove crucial in the future. The paper is co-authored by Dr. Morag Park, director of the MUHC Molecular Oncology Group, and Dr. Kalle Gehring, head of the Nuclear Magnetic Resonance Laboratory of the McGill University biochemistry department.
Similar news · Read more »
- Study questions 'cancer stem cell' hypothesis in breast cancer
03-12-2007 · EurekAlert!
A Dana-Farber Cancer Institute study challenges the hypothesis that "cancer stem cells" -- a small number of self-renewing cells within a tumor -- are responsible for breast cancer progression and recurrence, and that wiping out these cells alone could cure the disease.
Similar news · Read more »
- Drug that interrupts a key stage of cell division shows promise for advanced solid tumors
11-08-2006 · EurekAlert!
One of the first studies to investigate the effects of a new anti-cancer drug in patients with advanced or metastatic solid tumours has shown that it is capable of halting progression of the disease, and the study has provided the first proof of the drug's mechanism of action, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague was told on Wednesday.
Similar news · Read more »
- Why cisplatin kills breast cancer cells when other drugs fail
04-19-2007 · EurekAlert!
The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2. Individuals with such breast cancer (known as triple-negative breast cancer) do not respond to treatment with commonly used chemotherapeutic drugs and their prognosis is relatively poor. But a new study has indicated why triple-negative breast cancer cell lines are sensitive to exposure to the chemotherapeutic cisplatin.
Similar news · Read more »
- Cancer stem cells can go it alone
06-11-2007 · EurekAlert!
At the heart of most, if not all cancers, lie a handful of wayward stem cells that feed the ever growing tumor mass, but their scarcity make it difficult for scientists to study them. Now, times of plenty may lie ahead as a breast cancer cell line -- established long ago -- turned out to behave a lot like cancer stem cells.
Similar news · Read more »
- Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
11-08-2006 · EurekAlert!
Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague.
Similar news · Read more »
- Sutent achieves first line EAU approval for kidney cancer
03-22-2007 · EurekAlert!
Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.
Similar news · Read more »
- Study pries into ovarian cancer's deadly secrets
04-11-2007 · EurekAlert!
A new study sheds light on cell defects that lead to one common type of ovarian cancer and puts forth a promising new mouse model that already is being used for preclinical drug testing. The study focuses on ovarian endometrioid adenocarcinoma, the second most common form of a baffling, deadly disease for which early detection methods and effective treatments have been elusive so far.
Similar news · Read more »
